IP Library › Granted Patent US 11,773,381
Granted Patent B2
US 11,773,381 · App. 17/032,781 · Granted Oct 3, 2023

Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate

Inventor: Sang Jae Kim (Seoul, KR)
Assignee: Gem Vax & KAEL CO., LTD.
C12N9/1276A23L33/18A61K8/64A61K8/66A61K47/64A61K49/0002A61K49/0043A61K49/0056A61Q19/00C07K7/08C07K14/00G01N33/582A23V2002/00A61K38/00A61K2800/10A61K2800/57C07K2319/10G01N2458/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,773,381
App. No.
17/032,781
Granted
Oct 3, 2023
Kind
B2
Abstract

The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Claims (24)

1. A conjugate of a cell penetrating carrier peptide and a heterologous active ingredient, wherein the carrier peptide is 20 or less amino acids in length and comprises of is any one amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 79, and SEQ ID NO: 135, or the carrier peptide is 20 or less amino acids in length and has at least 80% sequence identity with any one of the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 79, and SEQ ID NO: 135 and maintains cell penetrating ability, and

wherein the carrier peptide and the active ingredient are combined via

a) a covalent bond, and optionally mediated by a linker; or

b) a non-covalent bond.

2. The conjugate according to claim 1 , wherein the active ingredient is at least one selected from protein, nucleic acid, peptide, lipid, glycol-lipid, mineral, sugar, nano-particle, biological products, contrast agent, drugs and chemical compounds.

3. The conjugate according to claim 2 , wherein the protein is a cytokine, antibody, fragment of antibody, therapeutic enzyme, soluble receptor or ligand.

4. The conjugate according to claim 2 , wherein the contrast agent is selected from the group consisting of a radiopaque contrast agent, paramagnetic contrast agent, superparamagnetic contrast agent and CT contrast agent.

5. The conjugate according to claim 2 , wherein the contrast agent is based on iron.

6. The conjugate according to claim 5 , wherein the contrast agent is a ferrocene carboxylate.

7. A contrast agent comprising a conjugate of claim 1 .

8. A contrast agent comprising a conjugate of claim 2 .

9. A contrast agent comprising a conjugate of claim 3 .

10. A contrast agent comprising a conjugate of claim 4 .

11. A contrast agent comprising a conjugate of claim 5 .

12. A contrast agent comprising a conjugate of claim 6 .

13. A composition comprising the conjugate according to claim 1 .

14. The composition according to claim 13 , wherein the active ingredient is selected from the group consisting of an active agent for treatment or prevention of disease, an active ingredient of functional cosmetics, and an active ingredient of health functional food; and wherein the composition is selected from the group consisting of a pharmaceutical composition, a cosmetic composition, and a health food composition.

15. A cell penetrating carrier peptide, wherein the carrier peptide is 20 or less amino acids in length and is any one amino acid sequence of SEQ ID NO: 79 and SEQ ID NO: 135, or the carrier peptide is 20 or less amino acids in length and has at least 80% sequence identity with any one of the amino acid sequence of SEQ ID NO: 79 and SEQ ID NO: 135 and maintains cell penetrating ability.

16. A polynucleotide that encodes the peptide according to claim 15 .

17. A vector that comprises the polynucleotide according to claim 16 .

18. A transformed cell that comprises the vector according to claim 17 .

19. A method of treating a subject having a mitochondrial-related disease or disorder comprising administering to the subject a pharmaceutical composition comprising the conjugate of claim 1 .

20. The method of claim 19 , wherein the pharmaceutical composition is administered though oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, in the bone marrow, epidural, or subcutaneous means.

21. The method of claim 19 , wherein the pharmaceutical composition comprises additives selected from the group consisting of diluents, excipients, lubricants, binders, disintegrants, buffers, dispersants, surfactants, coloring agents, aromatics, and sweeteners.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2020
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 054394/0819 →
Priority Claims (5)
KR 10-2012-0104144 · Sep 19, 2012 · national
KR 10-2012-0104173 · Sep 19, 2012 · national
KR 10-2012-0109207 · Sep 28, 2012 · national
KR 10-2012-0109216 · Sep 28, 2012 · national
KR 10-2013-0017169 · Feb 18, 2013 · national
Continuity (3)
Division 15869518 · Jan 12, 2018
Division 14429637
Related Publication 20210062167A1 · Mar 4, 2021